As the brain ages, many cell types succumb to senescence. How does this start? In the September 10 Nature Aging, scientists led by Wei Cai, Zhengqi Lu, and Quentin Liu at Sun Yat-Sen University, ...

Some evidence suggests that regular consumption of fish, nuts, fruits, veggies, and whole grains, aka the Mediterranean diet, reduces a person’s risk of dementia. APOE4, on the other hand, increases ...

Sponsor Chan Zuckerberg Biohub Network and the Chan Zuckerberg InitiativeDue Date November 13, 2025 ...

The network provides high-quality brain tissue to scientists and clinicians and supports major initiatives on research into neurological disorders, including the aims of the Ministerial Action Group ...

Summary The PS1 P264L knock-in mouse line was derived using a two-step mutagenesis strategy similar to that used to generate the TgAPPSwe-KI line (Reaume et al., 1996). An advantage to this model is ...

It has been clear for a while that anti-amyloid antibodies can sweep plaque from the brain, but until now the question of whether this slows cognitive decline has remained hotly contended. Despite ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

Introduction Despite being arguably the second most common dementing disorder, dementia with Lewy bodies, aka DLB, remains both mysterious and understudied. On Tuesday, October 10, 2017, the Lewy Body ...

Lifestyle changes have been touted as a way to prevent Alzheimer’s disease, but many of these, such as exercising more, are hard to implement. What if prevention were as simple as controlling your ...

In Alzheimer’s disease, defective autophagy seeds Aβ fibrils around the nuclei of neurons, which then burst, leaving amyloid plaques in their wake. This is according to researchers led by Ralph Nixon ...

The top-line results last September from Eisai’s Phase 3 trial of the anti-amyloid antibody lecanemab galvanized the field, but scientists said they needed to see the data before passing judgement.

On donanemab, younger people with fewer tangles benefitted the most. On lecanemab, too, people with the fewest tangles improved most on CDR-SB. In the DIAN prevention trial, eight years of ...